Jazz Pharmaceuticals PLC at Piper Jaffray Healthcare Conference Transcript
Okay. Let's get started. This is David Amsellem from the Piper Jaffray specialty pharma team. I'm delighted to kick off with our portion of the 31st Annual Piper Jaffray Healthcare Conference. Our first fireside chat is Jazz Pharmaceuticals, and we're delighted to have senior management with us today, Bruce Cozadd, CEO; and Rob Iannone, EVP, Head of R&D. So thank you both for joining us. I'll kick it over to you, Bruce, for maybe a couple of quick remarks, and then we can dive right into what at least will be for me a lot of questions.
Yes. So thank you, David. Good to be back. And let me start with the least interesting thing I'm going to say all day, which is we will make forward-looking statements, non-GAAP to GAAP reconciliations of all the figures I mentioned are on our website. And if I refer to guidance, I'm referring guidance to -- I'm referring to guidance we gave on our last
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |